HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Public ClinicalTrials.gov record NCT03911388. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Study identification
- NCT ID
- NCT03911388
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 24 participants
Conditions and interventions
Conditions
- Astrocytoma
- Astrocytoma, Cerebellar
- Brain Diseases
- Central Nervous System Diseases
- Central Nervous System Neoplasms, Malignant
- Central Nervous System Neoplasms, Primary
- Cerebellar Neoplasm Malignant Primary
- Cerebellar Neoplasm, Malignant
- Cerebellar Neoplasms
- Cerebellar Neoplasms, Primary
- Cerebellar PNET, Childhood
- Glioblastoma Multiforme
- Glioblastoma of Cerebellum
- HSV
- Medulloblastoma Recurrent
- Neoplasm Malignant
- Neoplasm Metastases
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms by Site
- Neoplasms, Brain
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Glandular and Epithelial
- Neoplasms, Nerve Tissue
- Neoplasms, Neuroepithelial
- Nervous System Cancer
- Nervous System Diseases
- Nervous System Neoplasms
- Neuroectodermal Tumors
- Neuroectodermal Tumors, Primitive
- Pediatric Brain Tumor
- Primitive Neuroectodermal Tumor (PNET) of Cerebellum
- Virus
Interventions
- G207 Biological
Biological
Eligibility (public fields only)
- Age range
- 3 Years to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 11, 2019
- Primary completion
- Aug 31, 2026
- Completion
- Aug 31, 2027
- Last update posted
- May 14, 2026
2019 – 2027
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's of Alabama | Birmingham | Alabama | 35233 | Active, not recruiting |
| St. Louis Children's Hospital | St Louis | Missouri | 63110 | Active, not recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03911388, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 14, 2026 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03911388 live on ClinicalTrials.gov.